Glycosaminoglycan derivatives and their use as inhibitors of tum

Details Glycosaminoglycan derivatives and their use as inhibitors of tum Glycosaminoglycan derivatives and their use as inhibitors of tum

1990-07-10

1993-11-16

Stone, Jacqueline

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 54, 536 21, A61K 31725, C08B 3710

Patent

active

052624030

ABSTRACT:
The present invention comprises a method for impeding the formation of tumor metastasis or tumor invasiveness in a host. Such inhibition comprises administration to the host of a glycosaminoglycan derivative substantially devoid of anticoagulation activity and is an effective inhibitory of heparanase activity. Such a glycosaminoglycan derivative may be provided by purchase or synthesis as directed herein. Parenteral administration to a tumor-bearing host of the glycosaminoglycan derivative results in the exposure of host-borne tumor cells thereto. Such exposure to effective levels of the derivative results in the inhibition of tumor heparanase activity and a lessening of invasiveness and metastatic spread.
Heparin, a glycosaminoglycan particularly effective as a heparanase inhibitor and an anti-clotting agent, is a preferred glycosaminoglycan for derivatization. Upon derivatization according to the present invention heparin may be converted into a glycosaminglycan derivative substantially devoid of anticoagulant activity but yet being an effective inhibitor of heparanase activity. Mere reduction of heparin carboxyl groups results in the production of a glycosaminoglycan derivative inhibitory to heparanase activity but without substantially anticoagulant activity non-anticoagulating, heparanase-inhibiting glycosaminoglycan derivatives may also be prepared from heparin, for example, by: at least partial N-desulfation and then N-acetylation; or N-, O-desulfation followed by N-resulfation.

REFERENCES:
patent: 2727889 (1955-12-01), Alburn
patent: 2755275 (1956-07-01), Cushing et al.
patent: 2831851 (1958-04-01), Vogler
patent: 3118816 (1964-01-01), Cushing
patent: 4727063 (1988-02-01), Naggi et al.
patent: 4882318 (1989-11-01), Vlodavsky et al.
Rong et al., Cancer, 57:586-590 (1986).
Nakajima et al., Cancer Metastasis: Experimental and Clinical Strategies, Welch et al. Eds., Alan R. Liss, New York, 113-122 (1986).
Folkman, Important Advance in Oncology, de Vita et al. Eds., J. B. Lippincott, Philadelphia, 42-62 (1985).
Castellot et al., J. Cell Physiol, 120:315-320 (1984).
Hilgard, Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects , Nicolson et al. Eds., Raven Press, New York, 353-360 (1984).
Folkman et al., Science, 221:719-725 (1983).
Irimura et al., Proc. Am. Soc. Cancer Res., 24:37, Abstract 144 (1983).
Nakajima et al., J. Biol. Chem., 259:2283-2290 (1984).
Nakajima et al., Science, 220:611-613 (1983).
Irimura et al., Anal. Biochem., 130:461-468 (1983).
Patent Cooperation Treaty International Application No. PCT/US91/04863 Search Report, Nov. 22, 1991.
Nicolson et al., Invasion Metastasis, 5:144-158 (1985).
Irimura et al., Gann Monogr. Cancer Res., 29:35-46 (1983).
Fisher et al., NCI Monograph, 1:35-43 (1986).
Vlodavsky et al., Cancer Res., 43:2704-2711 (1983).
Kramer et al., J. Biol. Chem., 257:2678-2686 (1982).
Nicolson, J. Hist. Cytochem., 30:214-220 (1982).
Nicolson, Biochem. Biophys., Acta, 695:113-176 (1982).
Guyton et al., Circulation Res., 46:625-634 (1980).
Hoover et al., Circ. Res., 47:578-583 (1980).
Tsubura et al., Gann Monograph on Cancer Research, 20:147-161 (1977).
Suemasu, Gann Monograph on Cancer Research, 20:163-172 (1977).
Hilgard et al., Eur. J. Cancer, 12:755-762 (1976).
Ross et al., Science, 180:1332-1339 (1973).
Michaels, Lancet, 2:832-833 (1964).
Nicolson, Exp. Cell Res., 150:3-22 (1984).
Oosta et al., J. Biol. Chem., 257:11249-11255 (1982).
PCT Search Report for UTSC:043PCT.
Inoue et al., Carbohydrate Res., 46:87-95 (1975).
Irimura et al., J. Cellular Biochem., Suppl. 9A, Abstracts of the 14th Annual Meeting, Jan. 12-Feb. 6, 1985.
Irimua et al., J. Cellular Biochem., Suppl. 10A, Abstracts of the 15th Annual Meeting, Jan. 20-Feb. 15, 1986, #A141.
Carr, Nature, 198:1104-1105 (1963).
Schirrmacher, Adv. Cancer Res., 43:1-73 (1985).
Oldberg et al., Biochemistry, 19:5755-5762 (1980).
Dialog Search Report.
Iverius, Biochem. J., 124:677-683 (1971).
Kanwar et al., J. Cell. Biol., 86:688-693 (1980).
Fransson et al., J. Biol. Chem., 256:13044-13047 (1981).
Hook et al., Anal. Biochem., 119:236-245 (1982).
Fransson et al., Carbohydrate Res., 110:135-144 (1982).
Nakajima et al., Cancer Letters, 31:277-283 (1986).
Irimura et al., Cancer Res., 41:3411-3418 (1981).
Nicolson et al., Cancer Res., 45:331-336 (1985).
Johnson et al., Cancer Treatment Rep., 69:821-824 (1985).
Nagasawa et al., Metho. Carbohyd. Chem., 8:287-289 (1980a).
Nagasawa et al., Metho. Carbohyd. Chem., 8:291-294 (1980b).
Cherniak et al., J. Biol. Chem., 239:2986-2990 (1964).
Taylor et al., Meth Carbohyd. Chem. 7:149-171 (1976).
Cappeletti et al., Anal. Biochem., 99:311-315 (1979).
Wang et al., Eur. J. Biochem., 153:125-130 (1985).
Fukuda et al., J. Biochem., 80:1223-1232 (1976).
Irimura et al., Biochem., 20:560-566 (1981).
Neri et al., J. Natl. Cancer Inst., 68:507-517 (1982).
Irimura et al., Biochemistry, 25:5322-5328 (1986).
Nakajima et al., Anal. Biochem., 157:162-171 (1986).

Affiliated with

Also associated with

Rating

Glycosaminoglycan derivatives and their use as inhibitors of tum does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glycosaminoglycan derivatives and their use as inhibitors of tum, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosaminoglycan derivatives and their use as inhibitors of tum will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-22643